Edgewise Therapeutics to Participate in Upcoming Investor Conferences

BOULDER, Colo.,Nov. 7, 2025/PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq:EWTX), a leading muscle disease biopharmaceutical company, today announced that management will participate in the following investor conferences:

The webcasts can be found on the EdgewiseEvents & Presentations pageand will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.

Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to:www.edgewisetx.comor follow us onLinkedIn,X,FacebookandInstagram.